Recent Finacing
Recent Raise
BioClin Therapeutics is a clinical-stage biopharma developing B-701, an anti-FGFR3 monoclonal antibody for metastatic urothelial carcinoma, evaluated in Phase 1b/2 monotherapy and combination trials with chemo and checkpoint inhibitors.
